Active Biotech AB (ACTI) AI Stock Analysis

• Market Cap: kr263.26M
• Dividend Yield: N/A
• Average Volume (3M): 10.51M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.72
• Revenue Growth: N/A
• EPS Growth: 24.47%
• Country: SE
• Employees: 6
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 1,230,164,700
• 10 Day Avg. Volume: 6,765,447
• 30 Day Avg. Volume: 10,507,323
• PEG Ratio: -0.27
• Price to Book (P/B): 11.76
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 32 Underperform
• Price Target: ―

Active Biotech AB's financial struggles are the most significant factor in its low stock score. The lack of revenue and persistent losses pose substantial risks, despite a stable debt level. Technical indicators do not suggest any immediate recovery, and the negative valuation metrics further underscore the challenges faced by the company.

Active Biotech AB Business Overview & Revenue Model

Company Description

Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.

How the Company Makes Money

Active Biotech AB generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies. These partnerships often involve licensing agreements, where Active Biotech licenses its drug candidates to partners for further development and commercialization. In return, Active Biotech receives upfront payments, milestone payments based on the achievement of specific developmental or regulatory milestones, and royalties on future sales of the licensed products. The company's revenue model is heavily reliant on the successful progression of its drug candidates through clinical trials, as well as the ability to secure and maintain strategic partnerships with industry leaders.

Active Biotech AB Financial Statement Overview

Summary

Active Biotech AB faces significant financial challenges, with no revenue generation and persistent losses. The low debt level on the balance sheet is positive, but the negative cash flow and lack of revenue are critical concerns, highlighting the need for better financial stability.

Income Statement

Active Biotech AB has consistently reported zero revenue for the past several years, indicating a lack of commercial success or monetization in its operations. The company has been operating at a net loss, with substantial negative EBIT and EBITDA margins, reflecting challenges in cost management and scalability. The absence of revenue growth and negative profit margins further highlight significant financial hurdles.

Balance Sheet

The company has maintained a low debt level, with Total Debt being zero in the latest report, which is a positive indication of financial prudence. The Stockholders' Equity has remained relatively stable, indicating a reasonable equity base. However, the overall equity ratio is moderate, suggesting a balanced but not overly strong financial position. Despite these strengths, the lack of revenue generation remains a critical concern.

Cash Flow

Active Biotech AB has been experiencing negative free cash flow, which reflects ongoing operational losses and insufficient cash generation to cover costs. The substantial operating cash outflows indicate a challenging environment for achieving profitability. Although financing cash flows have been positive, suggesting some external capital influx, the dependency on such measures is not sustainable in the long term.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	6.72M
Gross Profit	0.00	-1.68M	-1.49M	-1.28M	6.72M
EBITDA	-39.90M	-43.89M	-56.67M	-48.52M	-30.84M
Net Income	-39.40M	-45.80M	-58.69M	-49.88M	-32.12M
Balance Sheet
Total Assets	43.20M	44.05M	51.01M	56.80M	32.16M
Cash, Cash Equivalents and Short-Term Investments	27.40M	36.22M	41.80M	53.13M	26.21M
Total Debt	3.18M	4.54M	6.04M	986.00K	2.00M
Total Liabilities	11.13M	13.38M	16.49M	10.13M	10.04M
Stockholders Equity	32.07M	30.67M	34.51M	46.67M	22.11M
Cash Flow
Free Cash Flow	-40.40M	-45.74M	-55.09M	-46.17M	-32.22M
Operating Cash Flow	-40.40M	-45.74M	-54.85M	-46.17M	-32.22M
Investing Cash Flow	0.00	0.00	-245.00K	0.00	0.00
Financing Cash Flow	31.60M	40.16M	43.76M	73.09M	-1.25M

Active Biotech AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.21
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACTI, the sentiment is Positive. The current price of 0.21 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.21, and above the 200-day MA of 0.15, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 52.63 is Neutral, neither overbought nor oversold. The STOCH value of 41.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ACTI.

Active Biotech AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	50 Neutral	AU$2.61B	2.94	-57.47%	2.40%	36.37%	14.48%
ACTI	32 Underperform	kr263.26M	―	-186.40%	―	―	24.47%
0RK9	―	kr204.58M	―	-8427.12%	―	―	―
8N1	―	€11.09M	―	-56.71%	―	―	―
4YD	―	€11.81M	―	-180.76%	―	―	―
9II	―	€14.04M	―	-126.57%	―	―	―
1BD	―	€15.09M	―	-133.70%	―	―	―

Active Biotech AB Corporate Events

Active Biotech AB Announces 2025 Annual General Meeting

Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, where shareholders will discuss key resolutions including the re-election of board members and auditors, and the decision to carry forward the company’s accumulated loss without distributing dividends. This meeting is significant for stakeholders as it addresses the company’s governance and financial strategy moving forward.

Active Biotech Announces 2025 AGM and Board Re-elections

Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, in Lund, Sweden. The meeting will address standard AGM procedures including the election of board members and auditors, with the re-election of current board members and auditors proposed. The company has decided not to distribute dividends, opting instead to carry forward accumulated losses.

Active Biotech AB Announces 2025 Annual General Meeting

Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, in Lund, Sweden. Key agenda items include the re-election of board members and the decision to carry forward the company’s accumulated loss without paying dividends. The AGM will also address the re-election of Öhrlings PricewaterhouseCoopers AB as the company’s auditor, with no changes to the board’s remuneration.

Active Biotech AB Announces 2025 Annual General Meeting

Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, in Lund, Sweden. The meeting will address various resolutions, including the re-election of board members and auditors, and the proposal to carry forward the company’s accumulated loss without paying dividends. This AGM is significant for stakeholders as it outlines the company’s governance and financial strategies moving forward.

Active Biotech AB Announces Annual General Meeting and Key Resolutions

Active Biotech AB has announced its upcoming Annual General Meeting scheduled for May 28, 2025, where shareholders will discuss various resolutions including the re-election of board members and the proposal to carry forward the company’s accumulated loss without paying dividends. The meeting will also address the re-election of Öhrlings PricewaterhouseCoopers AB as the auditor, indicating a stable continuity in the company’s governance and financial oversight.

Active Biotech AB Announces 2025 Annual General Meeting Details

Active Biotech AB has announced its upcoming Annual General Meeting (AGM) scheduled for May 28, 2025. Key agenda items include the re-election of board members and auditors, with no dividend to be paid as the company’s accumulated loss will be carried forward. The meeting will also address board remuneration and share issue authorization, impacting the company’s governance and financial strategy moving forward.

Active Biotech AB Announces AGM and Key Resolutions

Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, where shareholders will discuss key resolutions including the re-election of board members and auditors, and the decision to carry forward the company’s accumulated loss without paying dividends. The AGM will also address board remuneration and share issue authorization, reflecting the company’s strategic focus on maintaining financial stability and governance continuity.

Active Biotech AB Announces 2025 Annual General Meeting

Active Biotech AB has announced its Annual General Meeting (AGM) scheduled for May 28, 2025, in Lund, Sweden. Shareholders are invited to participate, with key agenda items including the election of board members and auditors, and resolutions on the company’s financial statements. The board proposes no dividend distribution, opting to carry forward the accumulated loss, and recommends re-election of current board members and auditors.